Antibody engineers seek optimal drug targeting TIGIT checkpoint

被引：0
|
作者：
Elie Dolgin
机构：
来源：
Nature Biotechnology | 2020年 / 38卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Four antibodies are already in trials to test efficacy against the emerging checkpoint molecule TIGIT, but debate swirls around the importance of Fc binding for drug action.
引用
收藏
页码：1007 / 1009
页数：2
相关论文
共 50 条
  • [1] Antibody engineers seek optimal drug targeting TIGIT checkpoint
    Dolgin, Elie
    NATURE BIOTECHNOLOGY, 2020, 38 (09) : 1007 - 1009
  • [2] Publisher Correction: Antibody engineers seek optimal drug targeting TIGIT checkpoint
    Elie Dolgin
    Nature Biotechnology, 2020, 38 : 1357 - 1357
  • [3] Antibody engineers seek optimal drug targeting TIGIT checkpoint (vol 38, pg 1007, 2020)
    Dolgin, Elie
    NATURE BIOTECHNOLOGY, 2020, 38 (11) : 1357 - 1357
  • [4] Immune checkpoint targeting TIGIT in hepatocellular carcinoma
    Zheng, Qiuxian
    Xu, Jia
    Gu, Xinyu
    Wu, Fengtian
    Deng, Jingwen
    Cai, Xiaopeng
    Wang, Gang
    Li, Guojun
    Chen, Zhi
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2020, 12 (07): : 3212 - 3224
  • [5] Targeting TIGIT: Strengthening the Immune Checkpoint Blockade
    Paz-Ares Rodriguez, Luis
    ONCOLOGY-NEW YORK, 2021, 35 (01): : 44 - 47
  • [6] Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity
    Zhong, Zhenwei
    Zhang, Mengyao
    Ning, Yanan
    Mao, Guanchao
    Li, Xiaopei
    Deng, Qi
    Chen, Xiaorui
    Zuo, Dongliang
    Zhao, Xiangyu
    Xie, Ermin
    Wang, Huajing
    Guo, Lina
    Li, Bohua
    Xiao, Kai
    He, Xiaowen
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [7] Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity
    Zhenwei Zhong
    Mengyao Zhang
    Yanan Ning
    Guanchao Mao
    Xiaopei Li
    Qi Deng
    Xiaorui Chen
    Dongliang Zuo
    Xiangyu Zhao
    Ermin Xie
    Huajing Wang
    Lina Guo
    Bohua Li
    Kai Xiao
    Xiaowen He
    Scientific Reports, 12
  • [8] Development and functional characterization of COM902, a novel therapeutic antibody targeting the immune checkpoint TIGIT
    Kumar, Sandeep
    Desai, Radhika
    Cheng, Hsin-Yuan
    Hansen, Kyle
    Drake, Andy
    Wall, Patrick
    Logronio, Kathryn
    Cojocaru, Gady
    Hunter, John
    White, Mark
    Liang, Spencer
    Kotturi, Maya
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [9] TARGETING THE PD1 AND TIGIT CHECKPOINT PATHWAYS FOR ADULT AND PEDIATRIC GLIOMAS
    Shoger, Karsen
    McCarl, Lauren
    Gilbert, Ryan
    Villanueva, Clarence
    Levy, Nicole
    Amankulor, Nduka
    Pollack, Ian
    Kohanbash, Gary
    NEURO-ONCOLOGY, 2018, 20 : 125 - 125
  • [10] Double agents in immunotherapy: Unmasking the role of antibody drug conjugates in immune checkpoint targeting
    Ranganathan, Sruthi
    Reddy, Aswanth
    Russo, Alessandro
    Malepelle, Umberto
    Desai, Aakash
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 202
12345